Addressing analysts and portfolio managers at the corporate headquarters of Adams Respiratory Therapeutics Inc, Chester, NJ, Adams’ management unveiled nine new over-the-counter (OTC) products it intends to launch in early fiscal 2008.

The company also revealed that its new prescription product for cough, which was the subject of a New Drug Application filed with the FDA in December 2006, will contain extended-release guaifenesin in combination with codeine.

Additionally, management reviewed clinical data from the early analysis of the phase IIb trial for erdosteine and provided a sales modeling analysis.

For more detail, access the audio webcast and slides that accompany the company meeting by going to the investor relations section of the Adams Web site.